Pacific Biosciences reported Q4 revenue of $44.6 million, up 14% year‑over‑year, driven by record consumables sales and growth in clinical market adoption. PacBio shipped 21 Revio instruments and 42 Vega systems during the quarter and flagged development of SPRQ‑Nx, a next‑generation chemistry aimed at lowering long‑read sequencing costs. CEO Christian Henry cited a strengthened balance sheet following the sale of short‑read assets and said the company is positioned to drive adoption of long‑read platforms. PacBio reported a Q4 net loss but beat consensus on several top‑line metrics, underscoring commercialization traction for long‑read sequencing in research and clinical settings. Source: PacBio earnings release and CEO commentary.